Company & Sponsor Intelligence

University of Wisconsin, Madison

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials9

Recruiting1

Completed5

Countries1

Therapeutic footprint

adhdalzheimersanxietyautismdepressionepilepsyparkinsons

Indexed studies

NCT00204815Bone Mineral Density in Pediatric Epilepsy
epilepsy · United StatesCOMPLETED

NCT00585572Wisconsin Brain Donor Program
alzheimers · United StatesENROLLING_BY_INVITATION

NCT03523663System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2
adhd · United StatesTERMINATED

NCT0718207110-Week Physical Activity Program for Mothers of Children With Developmental Disabilities
autism · United StatesNA

NCT02358317Motor Learning and Brain Changes in Autism
autism · United StatesNA

NCT06110897RESISTance Exercise for Depression Trial
depression · United StatesNA

NCT01721460Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
parkinsons · United StatesPHASE4

NCT037710015Minutes4Myself: A Wellness Program for Caregivers
autism · United StatesNA

NCT02989493Testing Doxazosin to Treat Stress Mechanisms in Alcoholism
anxiety · United StatesPHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →